Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics 2024年第一季度GAAP每股收益美元（0.38美元）超过预期（0.41美元），销售额为22.0万美元，低于同比3.0万美元
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $22.000 thousand in sales this quarter. This is a 26.67 percent decrease over sales of $30.000 thousand the same period last year.
Allogene Therapeutics（纳斯达克股票代码：ALLO）公布的季度亏损为每股0.38美元，比分析师普遍预期的0.41美元（0.41美元）高出7.32％。这比去年同期每股亏损0.69美元（0.69美元）增长了44.93％。该公司报告本季度销售额为22,000美元。这比去年同期的3万美元销售额下降了26.67％。